Why the study?
Does the nonselective ET(A) and ET(B) receptor antagonist LU 420627 improve survival and ventricular remodeling in post-myocardial infarction rats?
Does the nonselective ET(A) and ET(B) receptor antagonist LU 420627 improve survival and ventricular remodeling in post-myocardial infarction rats?
Nonselective endothelin receptor antagonism with LU 420627 worsens survival and exacerbates ventricular dilatation and dysfunction in post-MI rats, with particularly unfavorable outcomes when initiated early.
Answers are grounded in this paper and cite their sources.
Nonselective ET antagonism harms post-MI survival in rats; leaves open selective blockade or human translation.
BACKGROUND: Some controversy exists as to the effects of endothelin (ET) receptor antagonism on long-term post-myocardial infarction (MI) evolution, particularly as it relates to the timing of the intervention after MI (<24 hours versus 10 days). METHODS AND RESULTS: Sham rats and rats surviving an acute MI for >20 hours (n=301) were assigned to treatment with saline or the nonselective ET(A) and ET(B) receptor antagonist LU 420627 (LU) started <24 hours (early) or 10 days (late) after MI and continued for 100 days. Long-term LU treatment led to increased mortality of rats with large MI, regardless of the timing of initiation of therapy. Early initiation of LU reduced survival from 61% to 16% (P<0.001 versus untreated), and later initiation reduced survival to 36% (P=0.012 versus untreated and P<0.001 versus early initiation). Early initiation of LU led to scar thinning, further left ventricular (LV) dilatation, LV dysfunction, and an excessive rise in right ventricular systolic pressure. Later initiation of LU did not modify scar formation but resulted in LV dilatation and dysfunction compared with the untreated group. Cardiac fibrosis tended to increase in the LU-treated MI groups. LU in the sham group reduced cardiac endothelial constitutive nitric oxide synthase but did not modify the changes that occurred with a large MI. CONCLUSIONS: The use of the nonselective ET(A) and ET(B) receptor antagonist LU results in reduced survival, ventricular dilatation, and dysfunction whether started early or late after MI. Early initiation of LU resulted in scar expansion and a particularly unfavorable outcome.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: